Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

BL1243 (tonabersat) is being developed as a potential oral treatment for patients with earlier-stage dry AMD, where treatment options remain limited Clinical development program expected to begin in 2027 VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced […]